
Back
Evolving Treatment Landscape in Relapsed and Refractory Multiple Myeloma
Explore evolving clinical considerations in relapsed and refractory multiple myeloma, drawing on recent clinical trial data, real-world evidence, and insights from major scientific meetings, including ASH 2025.
Evolving Treatment Landscape in Relapsed and Refractory Multiple Myeloma
Episodes
All
All



Explore how early-relapse multiple myeloma treatment shifts toward CAR T and bispecifics, weighing high-risk biology, kidney issues, logistics, and infection safety.

Experts weigh how to sequence myeloma therapies, highlighting where antibody-drug conjugates like belantamab fit when CAR-T or bispecific options aren’t feasible.

Early myeloma referral to academic centers helps patients access trials, avoid therapy pitfalls, and stay eligible for earlier CAR-T and bispecifics.










Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5
